水杨酰胺衍生物在抗病毒感染方面的治疗潜力。
Therapeutic potential of salicylamide derivatives for combating viral infections.
机构信息
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, USA.
出版信息
Med Res Rev. 2023 Jul;43(4):897-931. doi: 10.1002/med.21940. Epub 2023 Mar 10.
Since time immemorial human beings have constantly been fighting against viral infections. The ongoing and devastating coronavirus disease 2019 pandemic represents one of the most severe and most significant public health emergencies in human history, highlighting an urgent need to develop broad-spectrum antiviral agents. Salicylamide (2-hydroxybenzamide) derivatives, represented by niclosamide and nitazoxanide, inhibit the replication of a broad range of RNA and DNA viruses such as flavivirus, influenza A virus, and coronavirus. Moreover, nitazoxanide was effective in clinical trials against different viral infections including diarrhea caused by rotavirus and norovirus, uncomplicated influenza A and B, hepatitis B, and hepatitis C. In this review, we summarize the broad antiviral activities of salicylamide derivatives, the clinical progress, and the potential targets or mechanisms against different viral infections and highlight their therapeutic potential in combating the circulating and emerging viral infections in the future.
自古以来，人类一直在与病毒感染作斗争。正在肆虐的 2019 冠状病毒病大流行是人类历史上最严重和最重大的公共卫生突发事件之一，突出表明迫切需要开发广谱抗病毒药物。以硝氯酚和硝唑尼特为代表的柳氮酰胺（2-羟基苯甲酰胺）衍生物能够抑制多种 RNA 和 DNA 病毒的复制，如黄病毒、甲型流感病毒和冠状病毒。此外，硝唑尼特在针对包括轮状病毒和诺如病毒引起的腹泻、单纯性甲型和乙型流感、乙型肝炎和丙型肝炎在内的不同病毒感染的临床试验中也具有疗效。在这篇综述中，我们总结了柳氮酰胺衍生物的广谱抗病毒活性、临床进展以及针对不同病毒感染的潜在靶点或机制，并强调了它们在未来对抗流行和新发病毒感染方面的治疗潜力。
Zotero 插件